David Bond, Md
Clinical trials sponsored by David Bond, Md, explained in plain language.
-
Immunotherapy-Chemo combo shows promise for tough lymphoma
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can help people with aggressive B-cell non-Hodgkin lymphoma. About 30 adults with advanced stages of the disease are taking part. The main goal is to see how long the c…
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New combo therapy offers hope for Tough-to-Treat lymphomas
Disease control OngoingThis study tests a combination of two drugs, nivolumab and lenalidomide, in people with non-Hodgkin or Hodgkin lymphoma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combination works at shrinking tumors. Ab…
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC